Brief: Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.6 Vs. IBES Estimate USD 5.81
25/02/2025 21:05
Feb 25 (Reuters) - Jazz Pharmaceuticals Q4 net income USD 191.115 million. Q4 adjusted net income USD 405.863 million vs. IBES estimate USD 369.9 million Q4 revenue USD 1,088.173 million vs. IBES estimate USD 1,060 million Q4 EPS USD 3.11
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032